Mouse anti-Human CML Monoclonal Antibody | anti-CML antibody
CML, Human, mAb CML26
Reactivity
Human
Applications
Immunofluorescence, Western Blot
Synonyms
CML; Monoclonal Antibody; Human; mAb CML26; anti-CML antibody
Host
Mouse
Reactivity
Human
Clonality
Monoclonal
Isotype
Mouse IgG1
Form/Format
1 ml (100 ug/ml) 0.2 um filtered antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide
For unit size 0.5 mg or larger: PBS only (concentration< 0.5mg/ml)
For unit size 0.5 mg or larger: PBS only (concentration< 0.5mg/ml)
Applicable Applications for anti-CML antibody
F, Immunoassay (IA), Immunofluorescence (IF), P, Western Blot (WB)
Application Notes
Application Notes: P: fixation in 4% formalin; cardiac tissue sections (4 mm) deparaffinised for 10 min in xylene at room temperature, dehydrated by decreasing ethanol. Sections stained with haematoxylin and eosin. Blocking endogenous peroxidase activity with 0.3% hydrogen peroxide in methanol for 30 min. No heating to prevent artificial induction of CML. (Ref 1)
Application Use: For immunohistochemistry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user’s experimental setting.
Application Use: For immunohistochemistry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user’s experimental setting.
Immunogen
CML-KLH
Positive Control
Intramyocardial arteries
Preparation and Storage
Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
Related Product Information for anti-CML antibody
Product Description: The monoclonal antibody CML26 recognizes human CML (carboxymethyl-lysine). CML is known to be formed from the oxidation of both carbohydrates and lipids. This makes CML- a biomarker of general oxidative stress. Carboxymethyl-lysine (CML) is a well-characterized glycoxidation product that accumulates in tissues with age, and its rate of accumulation is accelerated in diabetes. Glycoxidation products are a subset of advanced glycation endproducts (AGEs) that are formed by the nonenzymatic glycation and subsequent irreversible oxidation of proteins. Oxidative stress and protein modification have been implicated in the pathogenesis of the chronic complications of diabetes, including nephropathy and atherosclerosis. The accumulation of CML in long-lived tissue such as skin collagen reflects oxidative stress over an extended period of the life-span, and has been shown to be greater in patients with diabetic complications than those without complications.
References
1. Bruynzeel, AM. Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. B J of Cancer 2007: 96, 937
2. Ciapaite J. Functioning of oxidative phosphorylation in liver mitochondria of high-fat diet fed rats. Biochim Biophys Acta. 2007, 1772:307.
3. Baidoshvili A. N(varepsilon)-(carboxymethyl)lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction?Arterioscler Thromb Vasc Biol. 2006, 26:2497.
4. Lieuw-a-Fa ML. Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb Haemost. 2006, 95:320.
5. van Heijst JW. Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis.Cancer Lett. 2006, 241:309.
6. Sommeijer DW. More fibrosis and thrombotic omplications but similar expression patterns of markers for coagulation and inflammation in symptomatic plaques from DM2 patients. J Histochem Cytochem. 2004, 52:1141
7. Schalkwijk CG. Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl) lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta. 2004, 221636:2
8. Baidoshvili A. N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. Atherosclerosis. 2004, 174:287.
2. Ciapaite J. Functioning of oxidative phosphorylation in liver mitochondria of high-fat diet fed rats. Biochim Biophys Acta. 2007, 1772:307.
3. Baidoshvili A. N(varepsilon)-(carboxymethyl)lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction?Arterioscler Thromb Vasc Biol. 2006, 26:2497.
4. Lieuw-a-Fa ML. Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb Haemost. 2006, 95:320.
5. van Heijst JW. Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis.Cancer Lett. 2006, 241:309.
6. Sommeijer DW. More fibrosis and thrombotic omplications but similar expression patterns of markers for coagulation and inflammation in symptomatic plaques from DM2 patients. J Histochem Cytochem. 2004, 52:1141
7. Schalkwijk CG. Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl) lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta. 2004, 221636:2
8. Baidoshvili A. N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. Atherosclerosis. 2004, 174:287.
Similar Products
Product Notes
The CML (Catalog #AAA584064) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The CML, Human, mAb CML26 reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's CML can be used in a range of immunoassay formats including, but not limited to, F, Immunoassay (IA), Immunofluorescence (IF), P, Western Blot (WB). Application Notes: P: fixation in 4% formalin; cardiac tissue sections (4 mm) deparaffinised for 10 min in xylene at room temperature, dehydrated by decreasing ethanol. Sections stained with haematoxylin and eosin. Blocking endogenous peroxidase activity with 0.3% hydrogen peroxide in methanol for 30 min. No heating to prevent artificial induction of CML. (Ref 1) Application Use: For immunohistochemistry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user’s experimental setting. Researchers should empirically determine the suitability of the CML for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "CML, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
